We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lung Cancer Pathology Pattern Predicts Recurrence

By LabMedica International staff writers
Posted on 21 Aug 2013
A specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

The pattern will help surgeons identify which patients are more likely to benefit from less radical lung-sparing surgery, and which patients will benefit from more extensive surgery.

Pathologists at the Memorial Sloan-Kettering Cancer Center (New York, NY, USA) evaluated the clinical characteristics and pathology information of 734 patients who had surgery for early-stage adenocarcinoma, the most common subtype of non-small-cell lung cancer. More...
The scientists evaluated the prognostic utility of a classification, called micropapillary (MIP) morphology, for patients with small, early-stage lung adenocarcinomas.

All available hematoxylin and eosin-stained slides were reviewed by two pathologists. A minimum of two hematoxylin and eosin stained slides were reviewed per patient; the median was four; and ranged from 2 to 10 slides/patient. Each tumor was evaluated by comprehensive histologic subtyping, and the percentage of each histologic component was recorded in 5% increments. They found that tumors in 40% of those patients exhibited an abnormal MIP cell pattern strongly associated with cancer recurrence after surgery.

The findings suggest that limited resection may not be appropriate for patients with the MIP pattern, as they were found to have a 34% risk of the cancer returning within five years after lung-sparing surgery, or limited resection, in which the tumor is removed by minimally invasive means and lung function is preserved. In contrast, patients with the MIP pattern who underwent lobectomy, the standard approach in which up to a third of the lung is removed along with the tumor, had only a 12% incidence of recurrence over a five-year period.

The scientists at Memorial Sloan-Kettering are working to develop new technology that can be used to precisely identify which tumors have the MIP pattern before or during surgery. This will not only help doctors recommend the most effective surgical approach for each patient, but will result in fewer patients requiring additional treatment. The study was published on August 7, 2013, in the Journal of the National Cancer Institute.

Related Links:

Memorial Sloan-Kettering Cancer Center

.




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.